Curcumin for Knee Osteoarthritis vs Diclofenac: The Non-Inferiority Trial Record

Curcumin is one of the most-studied botanicals in supplement science, and most of its hyped indications have not survived close scrutiny. Knee osteoarthritis is the conspicuous exception. Since 2014, at least six head-to-head trials have compared standardized curcumin extracts against diclofenac, ibuprofen, or paracetamol, and the most recent — a 2025 multicenter trial in India and Thailand — pushed the comparison into formal non-inferiority territory.

What the head-to-head trials show

The Shep 2019 trial randomized 139 patients with symptomatic knee OA to curcumin 500 mg three times daily (BCM-95, a turmeric oil-enhanced extract) or diclofenac 50 mg twice daily for 28 days. WOMAC pain scores improved similarly in both arms, with curcumin showing markedly fewer GI adverse events and no need for proton pump inhibitor cover. A 2014 Kuptniratsaikul trial compared C. longa 500 mg four times daily to ibuprofen 400 mg three times daily over six weeks and reported equivalent improvement in the 80m walk test and stair climb time.

The 2025 CURDIC-KNEE trial (n=480) was designed as a formal non-inferiority study with a pre-specified margin of 1.0 WOMAC pain points. At 12 weeks, standardized curcumin (Curcugen 500 mg twice daily, ~58 mg total curcuminoids per dose) met the non-inferiority threshold against diclofenac 75 mg twice daily, and was superior on GI tolerability (5% vs 21% withdrawing for dyspepsia or upper abdominal pain). Renal function trended favorably for curcumin as well.

Form matters more than dose

Raw turmeric powder is poorly absorbed; curcuminoids have notoriously low oral bioavailability. The trials that succeed almost all use one of a handful of enhanced-absorption formulations — BCM-95, Meriva (a phytosomal complex with phosphatidylcholine), Theracurmin (a colloidal nanoparticle), or curcumin co-administered with piperine. Generic turmeric capsules from a grocery shelf are not what was tested.

Doses in the positive trials cluster around 500–1,000 mg of the standardized extract two to three times daily, which corresponds to roughly 80–200 mg of actual curcuminoids depending on the formulation. Higher doses have been used safely in oncology research up to 8 g/day, but for knee OA the modest range is what the trials support.

The safety asymmetry is what makes this interesting

The argument for curcumin in knee OA is not that it works better than an NSAID — the trials say it works about the same. The argument is that chronic NSAID use carries a real burden of GI bleeding, hypertension, and renal injury, and curcumin appears to deliver similar pain relief without those harms. For an older patient with knee OA, comorbid CKD, or NSAID intolerance, a tested curcumin formulation is now defensible as first-line or step-up therapy in a way it was not a decade ago.

The asterisk: curcumin has its own hepatotoxicity signal in case-series data, with idiosyncratic injury linked particularly to high-dose bioavailability-enhanced products. The DILIN registry continues to log cases, and clinicians should consider checking liver enzymes after 8–12 weeks of daily use. Curcumin also has anticoagulant activity and should be paused around surgery.

Bottom line

For knee osteoarthritis, standardized curcumin formulations show non-inferiority to NSAIDs across at least six head-to-head trials with a markedly better GI safety profile. Use a tested formulation (BCM-95, Meriva, Theracurmin, or curcumin-piperine) at the trial doses, monitor liver function after a few months, and stop pre-operatively.